Profund Advisors
BBOT icon

Profund Advisors’s BridgeBio Oncology BBOT Stock Holding History

Profund Advisors’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-11,001
Closed -$83.8K – 1220
2026
Q2 		$83.8K Buy
+11,001
New +$91.8K ﹤0.01% 1154

Other funds holding BBOT

Regents of the University of California
Regents of the University of California Oakland, California $6.64B AUM 23.46% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Profund Advisors's BBOT Position: Q3 2026 in Review

Profund Advisors sold out of BridgeBio Oncology (BBOT) in Q3 2026, closing a stake of 11,001 shares — an estimated $83.8K sold.

Profund Advisors first reported a position in BBOT in Q2 2026 and held it in 1 quarter. The position peaked at $83.8K in Q2 2026. 6 funds tracked by Wall St. Rank hold BBOT as of Q3 2026.

  • Profund Advisors reported no remaining BridgeBio Oncology position as of Q3 2026 after selling out during the quarter.
  • Profund Advisors sold 11,001 BridgeBio Oncology shares in Q3 2026, an estimated $83.8K.
  • Profund Advisors first reported a position in BridgeBio Oncology in Q2 2026 and held it in 1 quarter.
  • Profund Advisors's BridgeBio Oncology position peaked at $83.8K in Q2 2026.
  • 6 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.